Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library

Pharmazie

Volumn 64, Issue 4, 2009, Pages 238-241

  Nagano, K ^a   Imai, S ^a   Mukai, Y ^a   Nakagawa, S ^a   Abe, Y ^a   Kamada, H ^a   Tsunoda, Shin Ichi ^a   Tsutsumi, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HYBRID PROTEIN; PROTEIN; PROTEIN BID; PROTEIN VENUS; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; PEPTIDE LIBRARY;

ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; CELL CULTURE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE, TUMOR; CELLS, CULTURED; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; RECOMBINANT FUSION PROTEINS;

EID: 66449093199     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8352     Document Type: Article

References (13)

1. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, Curiel DT (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 6: 3081-3087.
2. Berkova N, Lemay A, Korobko V, Shingarova L, Sagaidak L, Goupil S (1999) Tumor necrosis factor mutants with selective cytotoxic activity. Cancer Detect Prev 23: 1-7.
3. Cattaneo A, Biocca S (1999) The selection of intracellular antibodies. Trends Biotechnol 17: 115-121.
4. Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A, Ingram VM, Wittrup KD (2004) Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol 342: 901-912.
5. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM (2000) In vitro evolution of a T cell receptor with high affinity for peptide/ MHC. Proc Natl Acad Sci USA 97: 5387-5392.
6. Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antibodies 10: 127-142.
7. Imai S, Mukai Y, Nagano K, Shibata H, Sugita T, Abe Y, Nomura T, Tsutsumi Y, Kamada H, Nakagawa S, Tsunoda S (2006) Quality enhancement of the non-immune phage scFv library to isolate effective antibodies. Biol Pharm Bull 29: 1325-1330.
8. Miller TW, Messer A (2005) Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 12: 394-401.
9. Popkov M, Mage RG, Alexander C, Thundivalappil S, Barbas CF 3rd, Rader C (2003) Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325: 325-335.
10. Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF 3rd (2005) Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res 6: 972-981.
11. Rajpal A, Turi TG (2001) Intracellular stability of anti-caspase-3 intrabodies determines efficacy in retargeting the antigen. J Biol Chem 276: 33139-33146.
12. Worn A, Pluckthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305: 989-1010.
13. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400: 886-891.